Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study.

Zhang, Qiongwen; He, Ping; Tian, Tinglun; Yan, Xi; Huang, Juan; Zhang, Zhang; Zheng, Hong; Zhong, Xiaorong; Luo, Ting

Zhang, Qiongwen; He, Ping; Tian, Tinglun; Yan, Xi; Huang, Juan; Zhang, Zhang; Zheng, Hong; Zhong, Xiaorong; Luo, Ting.

Afiliación

Zhang Q; Department of Head and Neck Oncology, Department of Radiation Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.
He P; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Tian T; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yan X; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Huang J; Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Zhang Z; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Zheng H; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zhong X; Multi-omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Luo T; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Front Pharmacol ; 14: 1100556, 2023.

Article en En | MEDLINE | ID: mdl-37025489

Palabras clave

HER2-positive breast cancer; brain metastase; pyrotinib; real-world studies; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google